3.29
0.22 (7.17%)
| Previous Close | 3.07 |
| Open | 3.05 |
| Volume | 623,533 |
| Avg. Volume (3M) | 537,131 |
| Market Cap | 226,511,728 |
| Price / Sales | 1.95 |
| Price / Book | 0.670 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Profit Margin | -19.77% |
| Operating Margin (TTM) | -61.02% |
| Diluted EPS (TTM) | -0.420 |
| Quarterly Revenue Growth (YOY) | -44.70% |
| Total Debt/Equity (MRQ) | 3.58% |
| Current Ratio (MRQ) | 12.34 |
| Operating Cash Flow (TTM) | 27.37 M |
| Levered Free Cash Flow (TTM) | 12.04 M |
| Return on Assets (TTM) | -4.80% |
| Return on Equity (TTM) | -7.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | OraSure Technologies, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 0.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 4.83% |
| % Held by Institutions | 89.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Private Management Group Inc | 31 Mar 2026 | 5,422,129 |
| Altai Capital Management, L.P. | 31 Mar 2026 | 3,613,836 |
| Cannell Capital Llc | 31 Mar 2026 | 2,003,271 |
| Kotler Kevin | 31 Dec 2025 | 1,801,446 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BERTRAND JOHN D. | 2.97 | - | 33,661 | 99,973 |
| BOYD STEVEN KYLE | 2.99 | - | 75,000 | 224,000 |
| GAGLIANO NANCY J | - | 3.04 | -21,305 | -64,767 |
| MARMORA LELIO | - | 3.04 | -28,406 | -86,354 |
| MCMAHON ROBERT W. | - | 3.04 | -22,888 | -69,580 |
| Aggregate Net Quantity | 36,062 | |||
| Aggregate Net Value ($) | 103,272 | |||
| Aggregate Avg. Buy ($) | 2.98 | |||
| Aggregate Avg. Sell ($) | 3.04 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BOYD STEVEN KYLE | Director | 14 May 2026 | Buy (+) | 25,000 | 2.95 | 73,750 |
| GAGLIANO NANCY J | Director | 13 May 2026 | Disposed (-) | 21,305 | 3.04 | 64,767 |
| MCMAHON ROBERT W. | Director | 13 May 2026 | Disposed (-) | 22,888 | 3.04 | 69,580 |
| MARMORA LELIO | Director | 13 May 2026 | Disposed (-) | 28,406 | 3.04 | 86,354 |
| BOYD STEVEN KYLE | Director | 13 May 2026 | Buy (+) | 25,000 | 3.04 | 76,000 |
| BERTRAND JOHN D. | Director | 12 May 2026 | Acquired (+) | 33,661 | 2.97 | 99,973 |
| BOYD STEVEN KYLE | Director | 12 May 2026 | Buy (+) | 25,000 | 2.97 | 74,250 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |